Department of Neurology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
Crit Care Med. 2012 Nov;40(11):3070-82. doi: 10.1097/CCM.0b013e31825b931e.
Shivering after anesthesia or in the critical care setting is frequent, can be prolonged, and has the potential for serious adverse events and worsening outcomes. Furthermore, there are conflicting published data and clinical protocols on how to best treat shivering. In this study, we aimed to critically analyze the published evidence of antishivering medications.
We systematically reviewed, categorized, and analyzed all literature on antishivering medications published in English. Target key words and study types were determined and major scientific databases (PubMed, EMBASE, the Cochrane Controlled Trials Register, Ovid-Medline, and JAMA Evidence) and individual target journals were systematically searched up to August 1, 2011.
Publications were categorized by the pharmacological intervention used, regardless of whether the subjects were ventilated, underwent surgery, received anesthesia, or received additional medications. Randomized, double-blinded, placebo-controlled trials investigating antishivering treatment were extracted and evaluated for clinical and statistical homogeneity and, if suitable, included in a subsequent meta-analysis using linear comparisons calculating shivering risk-reduction ratios.
A total of 41 individual and eight combination antishivering medications were tested in 124 publications containing 208 substudies and recruiting a total of 9,668 subjects. Among those, 80 publications containing 119 substudies were identified as randomized, double-blinded, placebo-controlled of which 94 substudies were subjected to linear comparison analysis.
Study drug frequencies, calculated pooled risk benefits, and pooled numbers needed to treat of the five most frequently studied and efficacious medications were clonidine (22 studies; risk ratio: 1.6, numbers needed to treat: 4), meperidine (16; 2.2, 2), tramadol (8; 2.2, 2), nefopam (7; 2.1, 2), and ketamine (7; 1.8, 3).
There is significant heterogeneity in the literature with respect to study methods and efficacy testing of antishivering treatments. Clonidine, meperidine, tramadol, nefopam, and ketamine were the most frequently reported pharmacological interventions and showed a variable degree of efficacy in randomized, double-blinded, placebo-controlled trials.
麻醉后或重症监护环境下的寒战很常见,可能持续时间较长,并有发生严重不良事件和恶化转归的风险。此外,关于如何最佳治疗寒战,目前有相互矛盾的已发表数据和临床方案。本研究旨在批判性分析已发表的抗寒战药物文献。
我们系统地检索、分类和分析了所有以英文发表的抗寒战药物文献。确定了目标关键词和研究类型,并系统地检索了主要的科学数据库(PubMed、EMBASE、Cochrane 对照试验登记处、Ovid-Medline 和 JAMA Evidence)和个别目标期刊,检索截至 2011 年 8 月 1 日。
出版物按所使用的药理干预措施进行分类,无论患者是否接受通气、手术、麻醉或接受其他药物治疗。提取并评估了抗寒战治疗的随机、双盲、安慰剂对照试验,对其临床和统计学同质性进行评估,如果合适,使用线性比较计算寒战风险降低比,将其纳入后续的荟萃分析。
在 124 篇包含 208 项子研究的出版物中,共测试了 41 种单药和 8 种联合抗寒战药物,共纳入 9668 名患者。其中,80 篇出版物包含 119 项子研究,被确定为随机、双盲、安慰剂对照研究,其中 94 项子研究进行了线性比较分析。
五种最常研究和有效的药物的研究药物频率、计算的汇总风险效益和汇总需要治疗的病例数分别为可乐定(22 项研究;风险比:1.6,需要治疗的病例数:4)、哌替啶(16 项;2.2,2)、曲马多(8 项;2.2,2)、奈福泮(7 项;2.1,2)和氯胺酮(7 项;1.8,3)。
关于抗寒战治疗的研究方法和疗效检测,文献存在显著的异质性。可乐定、哌替啶、曲马多、奈福泮和氯胺酮是最常报道的药理干预措施,在随机、双盲、安慰剂对照试验中显示出不同程度的疗效。